StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report sent to investors on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Up 1,419,900.0 %
NASDAQ NBRV opened at $1.42 on Friday. The company has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $8.45. The company has a 50-day simple moving average of $0.14.
Nabriva Therapeutics Company Profile
Recommended Stories
- Five stocks we like better than Nabriva Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What Investors Need to Know About Upcoming IPOs
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.